GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agenus Inc (NAS:AGEN) » Definitions » Shiller PE Ratio

Agenus (Agenus) Shiller PE Ratio : (As of Apr. 26, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Agenus Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Agenus Shiller PE Ratio Historical Data

The historical data trend for Agenus's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agenus Shiller PE Ratio Chart

Agenus Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Agenus Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Agenus's Shiller PE Ratio

For the Biotechnology subindustry, Agenus's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Agenus's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agenus's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Agenus's Shiller PE Ratio falls into.



Agenus Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Agenus's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Agenus's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-2.4/129.4194*129.4194
=-2.400

Current CPI (Dec. 2023) = 129.4194.

Agenus Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.200 99.695 -0.260
201406 -2.600 100.560 -3.346
201409 -2.600 100.428 -3.351
201412 -8.200 99.070 -10.712
201503 -5.600 99.621 -7.275
201506 -10.600 100.684 -13.625
201509 -3.200 100.392 -4.125
201512 -3.600 99.792 -4.669
201603 -7.400 100.470 -9.532
201606 -6.600 101.688 -8.400
201609 -9.400 101.861 -11.943
201612 -6.000 101.863 -7.623
201703 -3.600 102.862 -4.529
201706 -6.400 103.349 -8.014
201709 -7.400 104.136 -9.197
201712 -7.000 104.011 -8.710
201803 -10.600 105.290 -13.029
201806 -4.800 106.317 -5.843
201809 -5.800 106.507 -7.048
201812 -8.000 105.998 -9.768
201903 2.400 107.251 2.896
201906 -7.600 108.070 -9.101
201909 -6.600 108.329 -7.885
201912 -4.400 108.420 -5.252
202003 -6.200 108.902 -7.368
202006 -5.600 108.767 -6.663
202009 -5.600 109.815 -6.600
202012 -3.600 109.897 -4.240
202103 -5.400 111.754 -6.254
202106 -7.400 114.631 -8.355
202109 14.400 115.734 16.103
202112 -6.000 117.630 -6.601
202203 -3.800 121.301 -4.054
202206 -3.400 125.017 -3.520
202209 -3.800 125.227 -3.927
202212 -4.800 125.222 -4.961
202303 -4.400 127.348 -4.472
202306 -4.000 128.729 -4.021
202309 -3.200 129.860 -3.189
202312 -2.400 129.419 -2.400

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Agenus  (NAS:AGEN) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Agenus Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Agenus's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Agenus (Agenus) Business Description

Traded in Other Exchanges
Address
3 Forbes Road, Lexington, MA, USA, 02421
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Executives
Ulf Wiinberg director
Steven J O'day officer: Chief Medical Officer 2344 BANYAN DRIVE, LOS ANGELES CA 90049
Garo H Armen officer: Chairman & CEO 3 FORBES ROAD, LEXINGTON MA 02421
Christine M Klaskin officer: VP Finance 3 FORBES ROAD, LEXINGTON MA 02421
Adam Krauss officer: Chief Legal Officer 139 GRANIT STREET, MEDFIELD MA 02052
Susan B Hirsch director 280 OLD SOMERSET ROAD, WATCHUNG NJ 07069
Paul N Clark director 5301 STEVENS CREEK BLVD, MS 1A-LC, SANTA CLARA CA 95051
Incyte Corp 10 percent owner 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Alex Duncan officer: Chief Technology Officer 3 FORBES ROAC, LEXINGTON MA 02421
Christian Cortis officer: See Remarks 3 FORBES ROAD, LEXINGTON MA 02421
Evan Kearns officer: V.P. and General Counsel AGENUS INC., 3 FORBES ROAK, LEXINGTON MA 02421
Jennifer Buell officer: Chief Operating Officer 3 FORBES ROAD, LEXINGTON MA 02421
Allison M Jeynes-ellis director FLAT 52, WILLIAM HUNT MANSIONS, LONDON X0 SW13 8HT
Wadih Jordan director ANTIGENICS INC., 162 FIFTH AVE., SUITE 900, NEW YORK NY 10010
Brian Corvese director C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900, NEW YORK NY 10010